The Bivalent Ligand Approach as a Tool for Improving the in vitro Anti??Alzheimer Multitarget Profile of Dimebon

…, E Soriano, J Marco??Contelles, V Andrisano…

文献索引：Rosini, Michela; Simoni, Elena; Bartolini, Manuela; Soriano, Elena; Marco-Contelles, Jose; Andrisano, Vincenza; Monti, Barbara; Windisch, Manfred; Hutter-Paier, Birgit; Mcclymont, David W.; Mellor, Ian R.; Bolognesi, Maria Laura ChemMedChem, 2013 , vol. 8, # 8 p. 1276 - 1281

全文：HTML全文

被引用次数: 11

摘要

Alzheimer's disease (AD) is an extremely challenging and often frustrating area of drug discovery. Since the withdrawal of tacrine (Cognex) in 2006, more than 200 AD drug candidates have failed in late-stage clinical trials.[1] The antihistamine drug dimebon (1, Figure 1) belongs to this long list. In 2008, 1 attracted considerable interest within the AD community when it successfully completed a small six-month clinical trial in Russia, in ...